Nikhil Lalwani, President and CEO of ANI Pharmaceuticals Inc. (NASDAQ: ANIP), sold 5,400 shares of the company's common stock on September 15, 2026, according to the source. The sale totaled $383,400, at a price of $71.00 per share.

The source says the sales were made under a Rule 10b5-1 trading plan that Lalwani adopted on May 26, 2026. After the transaction, he directly holds 339,089 shares, the source reports.

The source says the stock was trading near its 52-week low of $67.14 at the time. It also cites InvestingPro analysis suggesting the company is undervalued at current levels, with a P/E ratio of 14.38. That assessment is InvestingPro's, not a confirmed finding.

Separately, the source reports that ANI Pharmaceuticals posted stronger-than-expected third-quarter 2026 results, with adjusted earnings of $2.70 per share against an estimate of $2.18, and revenue of $290.8 million against a forecast of $280.8 million. The company also reduced its full-year sales guidance for Cortrophin Gel and announced plans for an acquisition to expand its rare-disease portfolio.